We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective.
- Authors
Coughlan, Diarmuid; Arisa, Oluwatomi; Thomson, Katie; Yu, Ge; Pearson, Fiona; Kernohan, Ashleigh; Gonzalez-Moral, Sonia Garcia; Wallace, Sheila; Rice, Stephen
- Abstract
This article discusses the introduction of disease severity modifiers in the National Institute for Health and Care Excellence (NICE) decision-making process. These modifiers replace the end-of-life premium criteria and allow decision makers to consider the severity of a disease when assessing the value of a treatment. The severity of the disease is determined by the absolute and proportional quality-adjusted life-year (QALY) shortfall. The article provides a case study on the use of disease severity modifiers in the appraisal of Trastuzumab Deruxtecan for the treatment of HER2-positive breast cancer. The document highlights the importance of accurately calculating the disease severity modifier and the impact it has on cost-effectiveness estimates. It also emphasizes the need for consistency in comparator quality-adjusted life years (QALY) estimates and the potential influence of different mapping algorithms. The authors conclude that future assessments should consider the uncertainty in comparator QALY estimates and request the NICE preferred mapping function from the company.
- Subjects
TRASTUZUMAB; HORMONE receptor positive breast cancer; EPIDERMAL growth factor receptors
- Publication
PharmacoEconomics, 2024, Vol 42, Issue 1, p5
- ISSN
1170-7690
- Publication type
Article
- DOI
10.1007/s40273-023-01317-z